Edratide (20-50 μg; s.c.; once a week for 10 weeks) exerts beneficial effects on SLE is through regulation of gene expression[2].
Edratide (50 μg/mouse; s.c.; 10 weekly) reduces the rates of apoptosis and down-regulates of caspase-8 and caspase-3, up-regulates Bcl-xL in SLE mouse[3].
| Animal Model: | 6-7 months female mice (with established SLE)[2] |
| Dosage: | 20-50 μg |
| Administration: | Subcutaneously injection; once a week for 10 weeks |
| Result: | Up-regulated the RNA transcripts of Tnfsf4, Il5ra, Zbtb20, Nid1, down-regulated the transcripts of Tfpi and S100a8. |
| Animal Model: | 7-8 months SLE-afflicted BWF1 female mice[3] |
| Dosage: | 50 μg/mouse |
| Administration: | S.c.; 10 weekly |
| Result: | Reduced apoptosis, down-regulated caspase-8 and caspase-3, and up-regulated Bcl-xL. |
